
Collegium Pharmaceutical (COLL) Stock Forecast & Price Target
Collegium Pharmaceutical (COLL) Analyst Ratings
Bulls say
Collegium Pharmaceutical is facing some short term challenges with the Nucynta franchise and uncertainty surrounding potential Belbuca generic competition, leading to a recent decrease in revenue guidance. However, the company's focus on responsible pain management and expansion into the ADHD market with Jornay PM and Azstarys show promise for long term growth. The recent growth of Jornay PM, with a mid-60% gross-to-net spread, and expanded ADHD-focused sales force also bodes well for future success. With a diverse portfolio and strong growth prospects, Collegium Pharmaceutical has a positive outlook for the future.
Bears say
Collegium Pharmaceutical is a biopharmaceutical company with a diversified portfolio of products focused on ADHD and pain treatment. Despite a strong initial quarter for Azstarys, concerns about generic competition for its pain management products and reliance on third-party suppliers may hinder the company's profitability in the future. However, its strong cash position and potential for business development opportunities could present some opportunities for growth and potential expansion into rare disease markets.
This aggregate rating is based on analysts' research of Collegium Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.
Collegium Pharmaceutical (COLL) Analyst Forecast & Price Prediction
Start investing in Collegium Pharmaceutical (COLL)
Order type
Buy in
Order amount
Est. shares
0 shares